Abstract | BACKGROUND: METHODS: RESULTS: Efficacy endpoint results: in the rivaroxaban group, there were 6 thrombotic events (1.7%), 2 cases with severe VTE (0.6%), and 3 cases with symptomatic VTE (0.9%). In the parnaparin group, there were 10 thrombotic events (3.1%), 4 cases with severe VTE (1.2%), and 6 cases with symptomatic VTE (1.9%). Safety endpoint results: in the rivaroxaban group, there were 21 cases with bleeding events (6.2%), 2 cases with severe bleeding (0.6%), and 19 cases with non-severe bleeding (5.6%). In the parnaparin group, there were 21 bleeding events (6.2%), 1 case with severe bleeding (0.3%), and 16 cases with non-severe bleeding (4.9%). The incidences of thromboembolic events, including severe and symptomatic VTE, were not significantly different between the two groups (P > 0.05). Bleeding event rates, including severe and non-severe bleeding, were also not significantly different. CONCLUSIONS:
Rivaroxaban proved to be equally effective as parnaparin for anticoagulation therapy, with both drugs exhibiting a similar prevention effect against postoperative VTE after lumbar spine surgery, without increasing the risk of postoperative bleeding.
|
Authors | Wei Du, Chunhong Zhao, Jingjie Wang, Jianqing Liu, Binghua Shen, Yanping Zheng |
Journal | Journal of orthopaedic surgery and research
(J Orthop Surg Res)
Vol. 10
Pg. 78
(May 23 2015)
ISSN: 1749-799X [Electronic] England |
PMID | 25998624
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Fibrinolytic Agents
- Heparin, Low-Molecular-Weight
- Rivaroxaban
- parnaparin
|
Topics |
- Fibrinolytic Agents
(therapeutic use)
- Heparin, Low-Molecular-Weight
(therapeutic use)
- Humans
- Lumbar Vertebrae
(surgery)
- Middle Aged
- Rivaroxaban
(therapeutic use)
- Treatment Outcome
- Venous Thromboembolism
(etiology, prevention & control)
|